News for Checkpoint Therapeutics, Inc. (CKPT)

Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhanc

PR NewswireNEW YORK, March 10, 2025 NEW YORK, March 10, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 700 points on Monday. The Dow traded down 1.43% to 42,190.51 while...

U.S. stocks traded lower this morning, with the Dow Jones index falling around 1% on Monday. Following the market opening Monday, the Dow traded down 1.01% to ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industri

U.S. stock futures declined on Monday after a small bout of relief on Friday as indices neared the correction zone.

(Bloomberg) -- Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here.Most Read from BloombergNJ College to Merge With State School After Financial StressTrump Administration Plans to Eliminate Dozens of Housing OfficesWhere New York City's Zoning Reform Will Add HousingBuffalo’s Billion-Dollar Freeway Fix Is on Ice, But Not Because of TrumpInside the ‘Not Architecture’ of High Line Designers Diller Scofidio + Re

ServiceNow nears largest acquisition yet with $3B Moveworks deal - report. DoorDash, TKO, Williams-Sonoma, Expand Energy joining S&P 500. Mark Carney to replace Justin Trudeau.

The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharm

Sun Pharma acquires Checkpoint Therapeutics for $355 million, expanding its oncology portfolio with innovative treatments.

PR NewswireMUMBAI, India and WALTHAM, Mass., March 9, 2025 Will add UNLOXCYTâ„¢ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment fo

Sun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company. The deal involves an upfront cash payment of $4.10 per share, totaling up to $355 million, with additional potential payouts based on milestones. The acquisition strengthens Sun Pharma's innovative portfolio in onco-derm therapy, particularly for advanced cutaneous squamous cell carcinoma.

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a significant stock transaction involving Checkpoint Therapeutics Inc (CKPT). The firm

/PRNewswire-PRWeb/ -- Women We Admire is pleased to announce The Top 50 Women Leaders in Healthcare for 2025. In a rapidly evolving healthcare landscape, these...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Checkpoint Therapeutics CEO sells $3.07 million in stock

See how Checkpoint Therapeutics, Inc.'s FDA-approved Unloxcyt drug for cSCC is set to disrupt the market with innovative pricing strategy. Click for my CKPT update.

U.S. stock futures were trading higher after the Nasdaq 100 extended its relentless climb last week, nearing the 22,000-point milestone.

UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIR